Circulating B-cell activating Factor in Multiple Myeloma Patients and its Correlations with Serum Levels of β2-Microglobulin and Interleukin-6
DOI:
https://doi.org/10.32007/jfacmedbaghdad2504Keywords:
B-cell activating factor, β2-microglobulin, Clinical stage, Interleukin -6, Multiple myelomaAbstract
Background: Multiple myeloma (MM) is characterized by clonal proliferation of malignant plasma cells within the bone marrow. In most patients, monoclonal immunoglobulin heavy chains or light chains are produced and are associated with organ dysfunction. The growth factor B-cell activating factor (BAFF) plays an important role in the pathogenesis of multiple myeloma due to its ability to promote B-cell survival, expansion, and differentiation.
Objective: to measure the circulatory level of B-cell activating factor in multiple myeloma patients in relapsed and remission states and explore its possible correlations with the clinical staging, β2-microglobulin, and interleukin-6.
Methods: This cross-sectional study was performed on 60 multiple myeloma patients with 30 in remission and 30 in relapse, as well as 20 healthy individuals serving as a control group. The study was conducted in the Hematology department of Baghdad Teaching Hospital in the Medical City Complex from January to September 2020. The enzyme-linked immunosorbent assay technique was used to measure plasma levels of B-cell activating factor, β2-microglobulin, and interleukin-6.
Results: The B-cell activating factor levels were significantly higher in multiple myeloma patients compared to the control, and in relapsed patients compared to those in remission. The level of B-cell activating factor increased with advanced disease, in both remission and relapsed states. There are positive correlations with β2-microglobulin and interleukin-6 levels in both relapsed and remission states, respectively.
Conclusion: Increased B-cell activating factor level in relapse more than remission states is a useful biomarker of disease activity in multiple myeloma and has positive correlations with β2-microglobulin and interleukin-6 levels.
Received: Sept. 2024
Revised: Aug. 2025
Accepted: Dec. 2025
Published Online: Dec. 2025
Published Dec. 2025
Downloads
References
1. Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. Int J Mol Sci. 2021 Apr 24;22(9):4462. https://doi.org/10.3390/ijms22094462. DOI: https://doi.org/10.3390/ijms22094462
2. Ahmed A, Killeen RB. Relapsed and Refractory Multiple Myeloma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://pubmed.ncbi.nlm.nih.gov/37276320/
3. Fragioudaki M, Boula A, Tsirakis G, Psarakis F, Spanoudakis M, Papadakis IS et al. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann Hematol. 2012;91(9):1413–8.
https://doi.org/10.1007/s00277-012-1470-x DOI: https://doi.org/10.1007/s00277-012-1470-x
4. Aziz K, Munjal K, Howe K, Yarchoan M. Mechanisms of B-Cell Activity in Tumor Microenvironment. International Journal of Radiation Oncology, Biology, Physics. 2024;120(2): e352-3. https://doi.org/10.1016/j.ijrobp.2024.07.776 DOI: https://doi.org/10.1016/j.ijrobp.2024.07.776
5. Nobari ST, Nojadeh JN, Talebi M. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. J Transl Med 2022;20(1):82. https://doi.org/10.1186/s12967-022-03285-y. DOI: https://doi.org/10.1186/s12967-022-03285-y
6. Lemancewicz D, Bolkun L, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, et al. Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features. Leuk Res. 2013;37(9):1089–93.
https://doi.org/10.1016/j.leukres.2013.05.014 DOI: https://doi.org/10.1016/j.leukres.2013.05.014
7. Tagami N, Yuda J, Goto Y. Current status of BAFF targeting immunotherapy in B-cell neoplasm. Int J Clin Oncol 2024;29:1676-83. https://doi.org/10.1007/s10147-024-02611-2 DOI: https://doi.org/10.1007/s10147-024-02611-2
8. Zhang T, Lin Z, Zheng Z, Wang Q, Zhou S, Zhang B, et al. Prognostic significance of β2-microglobulin decline index in multiple myeloma. Front Oncol. 2024;14:1322680. https://doi.org/10.3389/fonc.2024.1322680. DOI: https://doi.org/10.3389/fonc.2024.1322680
9. Salman AS, Saleh ES, Abass MS. Estimation of beta two microglobulins, fetuin-a, resistin serum levels in Iraqi multiple myeloma patients. Iraqi J Pharm Sci 2020;29(2):80-7. https://doi.org/10.31351/vol29iss2pp80-87 DOI: https://doi.org/10.31351/vol29iss2pp80-87
10. Mielnik M, Szudy-Szczyrek A, Homa-Mlak I, Mlak R, Podgajna-Mielnik M, Gorący A, et al. The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients. Biomedicines 2023;11(11):3012.
https://doi.org/10.3390/biomedicines11113012 DOI: https://doi.org/10.3390/biomedicines11113012
11. Bębnowska D, Hrynkiewicz R, Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska, et al. Immunological Prognostic Factors in Multiple Myeloma. International Journal of Molecular Sciences 2021;22(7):3587. https://doi.org/10.3390/ijms22073587 DOI: https://doi.org/10.3390/ijms22073587
12. Ramasamy K, Lonial S. Multiple myeloma. In: Hoffbrand AV, Mead AJ, Laffan MA, Collins GP, Hay D (eds.) Hoffbrand's Postgraduate Haematology. 8th ed. Bognor Regis, West Sussex, England: John Wiley & Sons Ltd; 2025. p.524-46.
https://content.e-bookshelf.de/media/reading/L-26506671-7e970491bf.pdf
13. International Myeloma Foundation. International Staging System (ISS) and Revised ISS (R-ISS). Last Medical Content Review: August 24, 2021. Available from:
https://www.myeloma.org/international-staging-system-iss-reivised-iss-r-iss
14. Baiee NH, Al-Rubaie HA. Plasma sclerostin level in multiple myeloma: Correlations with disease features and international staging system. Med J Babylon 2022;19(4):534–9. https://doi.org/10.4103/MJBL.MJBL_99_22 DOI: https://doi.org/10.4103/MJBL.MJBL_99_22
15. Salih ZM, Al-Rubaie HA. Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state. Iraqi Journal of Hematology 2023;12(1):8-12. https://doi.org/10.4103/ijh.ijh_23_23 DOI: https://doi.org/10.4103/ijh.ijh_23_23
16. Pan J, Sun Y, Zhang N, Li J, Ta F, Wei W, et al. Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance. Oncol Lett. 2017;14(3):2657–62. https://doi.org/10.3892/ol.2017.6528 DOI: https://doi.org/10.3892/ol.2017.6528
17. Jasrotia S, Gupta R, Sharma A, Halder A, Kumar L. Cytokine profile in multiple myeloma. Cytokine 2020;136:155271. https://doi.org/10.1016/j.cyto.2020.155271 DOI: https://doi.org/10.1016/j.cyto.2020.155271
18. Jasrotia S, Kumar L, Gupta R. Serum cytokine levels in patients of multiple myeloma at diagnosis and at relapse. Clinical Lymphoma, Myeloma and Leukemia. 2015;15:e252. https://doi.org/10.1016/j.clml.2015.07.535 DOI: https://doi.org/10.1016/j.clml.2015.07.535
19. Wang SM, Zhang TL, Jiang YM, Wu HY, Hao LM, Xing XH. Expression and significance of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011;19(2):395-8. Available from: https://pubmed.ncbi.nlm.nih.gov/21518495/
20. Bolkun L, Lemancewicz D, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, et al. BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. Ann Hematol. 2014;93(4):635–44. https://doi.org/10.1007/s00277-013-1924-9 DOI: https://doi.org/10.1007/s00277-013-1924-9
21. Alexandrakis MG, Roussou P, Pappa CA, Xekalou A, Goulidaki N, Boula A, et al. Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma. BioMed Research International 2013;2013:389579.
https://doi.org/10.1155/2013/389579 DOI: https://doi.org/10.1155/2013/389579
22. Sayed M, Mohammed MA, Khorshid O. Clinical evaluation of some biochemical markers in multiple myeloma among Egyptian patients. Journal of Medical Sciences 2007;7(6):942–51. https://doi.org/10.3923/jms.2007.942.951 DOI: https://doi.org/10.3923/jms.2007.942.951
23. Garewal H, Durie BG, Kyle RA, Bower B, Serokman R. Serum beta2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol. 1984;2(1):51–7. https://doi.org/10.1200/JCO.1984.2.1.51 DOI: https://doi.org/10.1200/JCO.1984.2.1.51
24. Brenning G, Wibell L, Bergstrom R. Serum β2‐microglobulin at remission and relapse in patients with multiple myeloma. Eur J Clin Invest. 1985;15(5):242-7. https://doi.org/10.1111/j.1365-2362.1985.tb00177.x DOI: https://doi.org/10.1111/j.1365-2362.1985.tb00177.x
25. Kyrstsonis MC, Dedou ssis G, Bax evanis C, Stamate lou M, Maniatis A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haematol. 1996;92(2):420-22.
https://doi.org/10.1046/j.1365-2141.1996.d01-1491.x DOI: https://doi.org/10.1046/j.1365-2141.1996.d01-1491.x
26. Jiang P, Yueguo W, Huiming H, Hongxiang Y, Mei W, Ju S. B-lymphocyte stimulator: a new biomarker for multiple myeloma. Eur J Haematol. 2009;82(4):267–76.
https://doi.org/10.1111/j.1600-0609.2008.01203.x DOI: https://doi.org/10.1111/j.1600-0609.2008.01203.x
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Wafaa F. Sahib, Haithem A. Al-Rubaie
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution 4.0 International license..
